Search Results

• SPINEJACK IN LIEU OF FORMAL CORPECTOMY CAGES: A CASE SERIES

  SpineJack in lieu of Formal Corpectomy Cages: A Case Series

• A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

• A Study Testing the Combo of Dasatinib or Imatinib to Chemo Treatment W/ Blinatumomab for Children, Adolescents, & YA W/ Ph+ or Ph-Like B-cell B-ALL

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

• Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis

  A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis

• Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II

• Endoscopic versus Shunt Treatment of Hydrocephalus in Infants (ESTHI)

  Endoscopic versus Shunt Treatment of Hydrocephalus in Infants (ESTHI)

• A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19

  A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized

• BRIUMVI® (ublituximab-xiiy) in the real-world setting

  Real World Experience With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal Registry Study (ENABLE)